Patents Assigned to STANDIGM INC
  • COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT
    Publication number: 20230414631
    Abstract: A composition for preventing or treating a TNF-?-related disease is disclosed. The composition includes hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient. The composition can effectively inhibit the expression or activity of TNF-? and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-?-related disease.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 28, 2023
    Applicants: SK CHEMICALS CO., LTD., STANDIGM INC
    Inventors: Soo Min LEE, Jong-ln KIM, Nam-Jin GU, Jeong-Hoon KIM, Dae Hee HAN, Hee Jung KOO